EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    3.1.1.4 | Aberrant Crypt Foci |
10025872 |
The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. |
ongoing research
unassigned |
3
0 |
| 3.1.1.4 | Aberrant Crypt Foci |
14690793 |
Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model. |
causal interaction
unassigned |
3
0 |
| 3.1.1.4 | Abscess |
33685059 |
[Research progress in the application of necrotic cavity lavage in the treatment of infected pancreatic necrosis]. |
causal interaction
therapeutic application
unassigned |
1
3
0 |
| 3.1.1.4 | Acalculous Cholecystitis |
1752395 |
Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2. |
ongoing research
unassigned |
3
0 |
| 3.1.1.4 | Acidosis |
2779534 |
Fatty acid oxidation and myocardial phospholipase A2 activity. |
diagnostic usage
ongoing research
unassigned |
3
3
0 |
| 3.1.1.4 | Acidosis |
9749826 |
Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis. |
unassigned |
0 |
| 3.1.1.4 | Acidosis |
26398495 |
Renal peroxiredoxin 6 interacts with anion exchanger 1 and plays a novel role in pH homeostasis. |
unassigned |
0 |
| 3.1.1.4 | Acidosis, Lactic |
2093421 |
Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach. |
unassigned |
0 |
| 3.1.1.4 | Acne Vulgaris |
19786821 |
Tetracycline Actions Relevant to Rosacea Treatment. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.1.1.4 | Acne Vulgaris |
28025036 |
Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
2
2
2
3 |
